June 28, 2022
June 28, 2022
Categories

The Summer 2022 advocacy blog, Considering Clinical Trials, is now available

Do you like it?
Read more
June 22, 2022
June 22, 2022
Categories

FDA approves dabrafenib plus trametinib for BRAF V600E-mutated tumors based on data from NCI-MATCH

Do you like it?
Read more
June 20, 2022
June 20, 2022
Categories

TMIST breast cancer trial looks to recruit underserved communities

Do you like it?
Read more
June 7, 2022
June 7, 2022
Categories

Pancreatic neuroendocrine tumors: Capecitabine plus temozolomide gives longer PFS than temozolomide alone

Do you like it?
Read more
June 7, 2022
June 7, 2022
Categories

E2108 evidence informs a discussion on systemic therapy vs surgery for de novo stage IV breast cancer

Do you like it?
Read more
June 6, 2022
June 6, 2022
Categories

Novel drug combination demonstrates promising results in treating pancreatic neuroendocrine tumors

Do you like it?
Read more
June 6, 2022
June 6, 2022
Categories

E2211: Dr. Pamela Kunz discusses the trial results and talks about the challenges of managing endocrine tumors

Do you like it?
Read more
June 6, 2022
June 6, 2022
Categories

Dr. Michael Atkins discusses the DREAMseq trial in patients with advanced melanoma

Do you like it?
Read more
June 5, 2022
June 5, 2022
Categories

Dr. Pamela Kunz on pancreatic neuroendocrine tumors: A final analysis of temozolomide or temozolomide plus capecitabine

Do you like it?
Read more
Load more
ECOG-ACRIN Cancer Research Group